Below is Validea's guru fundamental report for AXSOME THERAPEUTICS INC (AXSM). Of the 22 guru strategies we follow, AXSM rates highest using our Value Investor model based on the published ...

Axsome Therapeutics (AXSM) shares soared 20.2% in the last trading session to close at $127.08. The move was backed by solid volume with far more shares changing hands than in a normal session.

Biopharmaceutical firm Axsome Therapeutics (NASDAQ:AXSM) reported mixed fourth-quarter and full-year 2024 earnings on Tuesday, Feb. 18. The company achieved substantial revenue growth, with sales ...

Shares of Axsome Therapeutics (NASDAQ: AXSM) are up on Tuesday. The company's stock gained 4.1% as of 10:20 a.m. ET, but was up as much as 5.6% earlier in the day. The jump comes as the S&P 500 ...

Shares of Axsome Therapeutics (NASDAQ: AXSM) are flying higher on Monday. The company's stock is up 24.7% as of 1:10 p.m. ET, gaining as much as 25% earlier in the day. The move up comes as the S ...

AXSOME THERAPEUTICS ($AXSM) posted quarterly earnings results on Tuesday, February 18th. The company reported earnings of -$0.96 per share, beating estimates of -$1. ...

Below is a chart showing FSLY's trailing twelve month trading history, with the $10 strike highlighted in orange: And Axsome Therapeutics Inc (Symbol: AXSM) options are showing a volume of 6,987 ...

Axsome Therapeutics (AXSM) came out with a quarterly loss of $0.96 per share versus the Zacks Consensus Estimate of a loss of $1. This compares to loss of $0.73 per share a year ago. These figures ...

Nick Pizzie, the Chief Financial Officer of $AXSM, sold 3,000 shares of the company on 02-14-2025 for an estimated $393,210. We received data on the trade from a ...

Axsome Therapeutics (NASDAQ:AXSM – Get Free Report) had its target price increased by equities research analysts at HC ...

Axsome Therapeutics AXSM incurred an adjusted loss of 96 cents per share in the fourth quarter of 2024, wider than the Zacks Consensus Estimate of a loss of 90 cents. The company had incurred a ...

17 analysts have expressed a variety of opinions on Axsome Therapeutics (NASDAQ:AXSM) over the past quarter, offering a diverse set of opinions from bullish to bearish. The following table ...